Please assess the completion status of the following clinical trial:

Trial Title: Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged over 18 years~* Men or non-pregnant women~* Patients with a diagnosis of ulcerative colitis who requires to start VDZ~* Moderate to severe active ulcerative colitis defined as a total mayo score ranging from 6 to 12 and endoscopic Mayo score above 1~* UC patients with previous failure with TNF antagonist agents and unacceptable side-effects from steroids, and/or immunosuppressive agents (i.e., azathioprine, 6-mercaptopurine, or methotrexate).~* oral prednisone, are allowed at stable dose for at least 4 weeks-before inclusion. Concomitant immunosuppressive agents, mesalamine, are allowed at stable dose for at least three months before inclusion. Steroid tapering has to be set up at Week 6 after starting VDZ, according to the European Crohn's and Colitis Organisation (ECCO) recommendations.~* Informed written consent given.~Exclusion Criteria:~* Existing pregnancy, lactation, or intended pregnancy within the next 15 months~* Minors or History of disease, including mental/emotional disorder that might interfere with their participation in the study~* Serious secondary illnesses of an acute or chronic nature, which in the opinion of the investigator renders the patient unsuitable for inclusion into the study~* Inability to comply with the protocol requirements~* Inability to fill in the diary cards during the last 3 days before each visit~* Severe Acute UC needed hospitalisation~* Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years)~* Short bowel syndrome~* Previous treatments with vedolizumab, natalizumab, efalizumab or rituximab.~* Previous treatment with adalimumab within 30 days prior enrollment or infliximab and certolizumab pegol within 60 days before enrollment (This period may be shortened in the opinion of the investigator.)~* Prior extensive colonic resection, obstructive (symptomatic) intestinal stricture, abdominal abscess, active or latent tuberculosis,~* Clostridium difficile superinfection;~* Indeterminate colitis~* Concomitant leukocyte apheresis.~* Any contraindication to vedolizumab therapy~* Patients who denied the protocol, not ability to accept or sign consent of the protocol~* Subject involved in another interventional clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis patients (Type: EXPERIMENTAL): To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization.

Based on this trial design, predict the completion outcome and termination type (if applicable).